Naturally acquired immune responses to P. vivax merozoite surface protein 3α and merozoite surface protein 9 are associated with reduced risk of P. vivax malaria in young Papua New Guinean children.
Naturally acquired immune responses to P. vivax merozoite surface protein 3α and merozoite surface protein 9 are associated with reduced risk of P. vivax malaria in young Papua New Guinean children.
复制标题
天然获得的对息肉气蛋白石蛋白表面蛋白3α和梅洛唑岩表面蛋白9的免疫反应与新几内亚儿童的幼虫假单胞菌疟疾的风险降低有关。
DOI：
10.1371/journal.pntd.0002498
复制
发表时间：
2013-11
影响因子：
3.8
通讯作者：
Mueller I
中科院分区：
文献类型：
--
作者：
Stanisic DI;Javati S;Kiniboro B;Lin E;Jiang J;Singh B;Meyer EV;Siba P;Koepfli C;Felger I;Galinski MR;Mueller I
间日疟原虫是地理分布最广的人类疟疾寄生虫。在巴布亚新几内亚进行的队列研究发现，生活在疟疾高度流行地区的儿童对间日疟迅速产生免疫力。尽管许多间日疟原虫裂殖子抗原是天然获得的抗体的靶标，但这些抗体中的许多抗体在保护性免疫中的作用尚不清楚。在1-3岁的儿童队列中，测量了裂殖子表面蛋白3α（PvMSP 3 α）和裂殖子表面蛋白9（PvMSP 9）不同区域的抗体，并在16个月的主动随访期间将其与间日疟原虫疟疾的预期风险相关。总体而言，PvMSP 3 α和PvMSP 9蛋白抗体的患病率较低（9-65%）。PvMSP 3 α N-末端、Block I和Block II区域的抗体随着年龄的增长而显著增加，而PvMSP 3 α Block I和PvMSP 9 N-末端区域的抗体与并发间日疟原虫感染呈正相关。与暴露量（定义为随时间推移获得的遗传学上不同的血液阶段感染的数量（molFOB））和年龄无关，PvMSP 3 α Block II（校正的发病率比（aIRR）= 0.59，p = 0.011）和PvMSP 9 N末端（aIRR = 0.68，p = 0.035）特异性抗体与预防临床间日疟原虫疟疾相关。 这种保护对高密度感染最为明显。对于PvMSP 3 α Block II，抗体水平越高，效果越强。这些结果表明，PvMSP 3 α Block II和PvMSP 9 N-末端应进一步研究其作为间日疟原虫疫苗抗原的潜力。控制molFOB可确保观察到的相关性不会受到暴露个体差异的混淆。 间日疟原虫是地理分布最广的人类疟疾寄生虫。在高度流行的地区，如巴布亚新几内亚，观察到对间日疟的免疫力非常迅速。尽管已知许多间日疟原虫裂殖子抗原是天然获得的抗体的靶标，但这些抗体中的许多抗体在保护性免疫中的作用尚不清楚。在183名1-3岁儿童的队列中，我们现在表明裂殖子表面蛋白3α（PvMSP 3 α）和裂殖子表面蛋白9（PvMSP 9）抗体的存在与间日疟原虫疟疾负担的显著减少有关。抗体随着年龄的增长和并发间日疟原虫感染的存在而增加。在调整了年龄和暴露的个体差异后，在PvMSP 3 α Block II（降低41%，p = 0.001）和PvMSP 9 N-末端区域抗体的儿童中观察到风险降低最明显。 (32%减少，p = 0.035）。 这些结果表明，PvMSP 3 α Block II和PvMSP 9 N-末端应进一步研究其作为间日疟原虫疫苗抗原的潜力。
Plasmodium vivax is the most geographically widespread human malaria parasite. Cohort studies in Papua New Guinea have identified a rapid onset of immunity against vivax-malaria in children living in highly endemic areas. Although numerous P. vivax merozoite antigens are targets of naturally acquired antibodies, the role of many of these antibodies in protective immunity is yet unknown. In a cohort of children aged 1–3 years, antibodies to different regions of Merozoite Surface Protein 3α (PvMSP3α) and Merozoite Surface Protein 9 (PvMSP9) were measured and related to prospective risk of P. vivax malaria during 16 months of active follow-up. Overall, there was a low prevalence of antibodies to PvMSP3α and PvMSP9 proteins (9–65%). Antibodies to the PvMSP3α N-terminal, Block I and Block II regions increased significantly with age while antibodies to the PvMSP3α Block I and PvMSP9 N-terminal regions were positively associated with concurrent P. vivax infection. Independent of exposure (defined as the number of genetically distinct blood-stage infection acquired over time (molFOB)) and age, antibodies specific to both PvMSP3α Block II (adjusted incidence ratio (aIRR) = 0.59, p = 0.011) and PvMSP9 N-terminus (aIRR = 0.68, p = 0.035) were associated with protection against clinical P. vivax malaria. This protection was most pronounced against high-density infections. For PvMSP3α Block II, the effect was stronger with higher levels of antibodies. These results indicate that PvMSP3α Block II and PvMSP9 N-terminus should be further investigated for their potential as P. vivax vaccine antigens. Controlling for molFOB assures that the observed associations are not confounded by individual differences in exposure. Plasmodium vivax is the most geographically widespread human malaria parasite. In highly endemic areas such as Papua New Guinea, a very rapid onset of immunity against vivax-malaria is observed. Although it is known that numerous P. vivax merozoite antigens are targets of naturally acquired antibodies, the role of many of these antibodies in protective immunity is yet unknown. In a cohort of 183 children aged 1–3 years, we now show that the presence of antibodies to Merozoite Surface Protein 3α (PvMSP3α) and Merozoite Surface Protein 9 (PvMSP9) are associated with a significant reduction in the burden P. vivax malaria. Antibodies increased with age and in the presence of concurrent P. vivax infections. After adjusting for both age and individual differences in exposure, the strongest reductions in risk were seen in children with antibodies to PvMSP3α Block II (41% reduction, p = 0.001) and PvMSP9 N-terminal region. (32% reduction, p = 0.035). These results indicate that PvMSP3α Block II and PvMSP9 N-terminus should be further investigated for their potential as P. vivax vaccine antigens.
登录
查看更多内容
疟原虫的抗原性和免疫原性蛋白质表面蛋白-3。
影响因子：
3.7
作者：
Bitencourt AR;Vicentin EC;Jimenez MC;Ricci R;Leite JA;Costa FT;Ferreira LC;Russell B;Nosten F;Rénia L;Galinski MR;Barnwell JW;Rodrigues MM;Soares IS
通讯作者：
Soares IS
影响因子：
15.8
作者：
Grimberg, Brian T.;Udomsangpetch, Rachanee;King, Christopher L.
通讯作者：
King, Christopher L.
DOI：
10.4269/ajtmh.2003.68.613
发表时间：
2003-05-01
影响因子：
3.3
作者：
Cui, LW;Mascorro, CN;Sattabongkot, J
通讯作者：
Sattabongkot, J
影响因子：
2.2
作者：
Egan, AF;Burghaus, P;Riley, EM
通讯作者：
Riley, EM
影响因子：
1.5
作者：
Galinski, MR;Ingravallo, P;Barnwell, JW
通讯作者：
Barnwell, JW